Abstract
In contrast to the insidious and poorly immunogenic human papillomavirus (HPV) infections, vaccination with the HPV virus-like particles (vlps) is non-infectious and stimulates a strong neutralizing-antibody response that protects HPV-naïve vaccinees from viral infection and associated cancers. However, controversy about alleged adverse events following immunization (AEFI) with the vlps have led to extensive reductions in vaccine acceptance, with countries like Japan dropping it altogether. The AEFIs are grouped into chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). In this review, we present a hypothesis that the AEFIs might arise from malfunctions within the immune system when confronted with the unusual antigen. In addition, we outline how the pathophysiology of the AEFIs can be cost-effectively investigated with the holistic principles of systems vaccinology in a two-step process. First, comprehensive immunological profiles of HPV vaccinees exhibiting the AEFIs are generated by integrating the data derived from serological profiling for prominent HPV antibodies and serum cytokines, with data from serum metabolomics, peripheral white blood cells transcriptomics and gut microbiome profiling. Next, the immunological profiles are compared with corresponding profiles generated for matched (a) HPV vaccinees without AEFIs; (b) non-HPV-vaccinated individuals with CFS/ME-like symptoms; and (c) non-HPV-vaccinated individuals without CFS/ME. In these comparisons, any causal links between HPV vaccine and the AEFIs, as well as the underlying molecular basis for the links will be revealed. Such a study should provide an objective basis for evaluating HPV vaccine safety and for identifying biomarkers for individuals at risk of developing AEFI with HPV vaccination.
Similar content being viewed by others
Abbreviations
- HPV:
-
Human papillomavirus
- AEFI:
-
Adverse events following immunization
- CFS/ME:
-
Chronic fatigue syndrome/myalgic encephalomyelitis
- DC:
-
Dendritic cells
- APC:
-
Antigen-presenting cell
- BCR:
-
B cell receptor
- TCR:
-
T cell receptor
References
World Health Organization (WHO) (2018) Human papillomavirus (HPV) and cervical cancer at http://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer. Accessed 8 Oct 2018
Mariani L, Venuti A (2010) HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med 8:105. https://doi.org/10.1186/1479-5876-8-105
Paul WE (2011) Bridging innate and adaptive immunity. Cell 147(6):1212–1215
Larson HJ, Wilson R, Hanley S et al (2014) Tracking the global spread of vaccine sentiments: the global response to Japan’s suspension of its HPV vaccine recommendation. Hum Vaccines Immunother 10(9):2543–2550
Brinth L, Pors K, Hoppe AAG et al (2015) Is chronic fatigue syndrome/myalgic encephalomyelitis a relevant diagnosis in patients with suspected side effects to human papilloma virus vaccine? Int J Vaccines Vaccin 1(1):00003. https://doi.org/10.15406/ijvv.2015.01.00003
Global Advisory Committee on Vaccine Safety (2017) Safety update of HPV vaccines at http://www.who.int/vaccine_safety/committee/reports/June_2017/en/. Accessed 8 Oct 2018
Danish Health Authority, news (2016) Sharp fall in HPV vaccination rate at https://www.sst.dk/en/news/2016/sharp-fall-in-hpv-vaccination-rate. Accessed 8 Oct 2018
Brodin P, Jojic V, Gao T et al (2015) Variation in the human immune system is largely driven by non-heritable influences. Cell 160:37–47. https://doi.org/10.1016/j.cell.2014.12.020
Brodin P, Davis MM (2017) Human immune system variation. Nat Rev Immunol 17(1):21–29. https://doi.org/10.1038/nri.2016.125
Hagana T, Nakaya HI, Subramaniam S et al (2015) Systems vaccinology: enabling rational vaccine design with systems biological approaches. Vaccine 33(40):5294–5301. https://doi.org/10.1016/j.vaccine.2015.03.072
Querec TD, Akondy RS, Lee EK et al (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10(1):116–125. https://doi.org/10.1038/ni.1688
Avey S, Cheung F, Fermin D et al (2017) Multicohort analysis reveals baseline transcriptional predictors of influenza vaccination responses (HIPC-CHI Signatures Project Team and HIPC-I Consortium). Sci Immunol 2(14):eaal4656. https://doi.org/10.1126/sciimmunol.aal4656
Burd EM (2003) Human papillomavirus and cervical cancer. Clin Microbiol Rev 16(1):1–17
Longworth MS, Laimins LA (2004) Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68(2):362–372
Fehrmann F, Laimins LA (2003) Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 22:5201–5207
Smith JS, Lindsay L, Hoots B et al (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121(3):621–632
Ashrafi GH, Haghshenas MR, Marchetti B et al (2005) E5 protein of human papillomavirus type 16 selectively downregulates surface HLA. Int J Cancer 113:276–283
Sapp M, Volpers C, Muller M, Streck RE (1995) Organization of the major and minor capsid proteins in human papillomavirus type 33 virus-like particles. J Gen Virol 76:2407–2412
Buck CB, Cheng N, Thompson CD et al (2008) Arrangement of L2 within the papillomavirus capsid. J Virol 82:5190–5197
Conway MJ, Meyers C (2009) Replication and assembly of human papillomaviruses. J Dent Res 88(4):307–317. https://doi.org/10.1177/0022034509333446
Zheng Z-M, Baker CC (2006) Papillomavirus genome structure, expression and post-transcriptional regulation. Front Biosci 11:2286–2302
Sterlinko GH, Weber M, Elston R et al (2004) Inhibition of E6-induced degradation of its cellular substrates by novel blocking peptides. J Mol Biol 335:971–985
Yim EK, Park JS (2005) The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat 37(6):319–324
Hasan UA, Bates E, Takeshita F et al (2007) TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178:3186–3197
Kanodia S, Fahey LM, Kast WM (2007) Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 7:79–89
Moscicki AB, Schiffman M, Kjaer S, Villa LL (2006) Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 24(Suppl 3):S3-42–S3-51
Roden RBS, Lowy DR, Schiller JT (1997) Papillomavirus is resistant to desiccation. J Infect Dis 176:1076–1079
zur Hausen H H, de Villiers EM (1994) Human papillomaviruses. Annu Rev Microbiol 48:427–447
Walboomers JMM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19
Laimins LA (1993) The biology of human papillomaviruses: from warts to cancer. Infect Agents Dis 2(2):74–86
Vinokurova S, Wentzensen N, Kraus I et al (2008) Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 68(1):307–313
Joura EA, Giuliano AR, Ole-Erik Iversen O et al (2015) A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372:711–723. https://doi.org/10.1056/NEJMoa1405044
Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8(12):958–969. https://doi.org/10.1038/nri2448
Epelman S, Kory J, Lavine KJ, Randolph GJ (2014) Origin and functions of tissue macrophages. Immunity 41(1):21–35. https://doi.org/10.1016/j.immuni.2014.06.013
Chávez-Galán L, Olleros ML, Vesin D, Garcia I (2015) Much more than M1 and M2 macrophages, there are also CD169+ and TCR+ macrophages. Front Immunol 6:263. https://doi.org/10.3389/fimmu.2015.00263
Kobayashi SD, DeLeo FR (2009) Towards a comprehensive understanding of the role of neutrophils in innate immunity: a systems biology-level approach. Wiley Interdiscip Rev Syst Biol Med 1(3):309–333. https://doi.org/10.1002/wsbm.32
Tak T, Tesselaar K, Pillay J et al (2013) What’s your age again? Determination of human neutrophil half-lives revisited. J Leukoc Biol 94:595–601
Lakschevitz FS, Hassanpour S, Rubin A et al (2016) Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res 342(2):200–209. https://doi.org/10.1016/j.yexcr.2016.03.007
Steinman RM (2006) Introduction to some of the issues and mysteries considered in this book on dendritic cells. In: Lutz MB, Romani N, Steinkasserer A (eds) Handbook of Dendritic Cells. Biology, Diseases, and Therapies, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 3–11
Geissmann F, Manz MG, Jung S et al (2010) Development of monocytes, macrophages and dendritic cells. Science 327(5966):656–661
Collin M, McGovern N, Haniffa M (2013) Human dendritic cell subsets. Immunology 140(1):22–30
Helft J, Ginhoux F, Bogunovic M, Merad M (2010) Review Origin and functional heterogeneity of non-lymphoid tissue dendritic cells in mice. Immunol Rev 234(1):55–75
Merad M, Sathe P, Helft J et al (2013) The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. https://doi.org/10.1146/annurev-immunol-020711-074950
Shamri R, Xenakis JJ, Spencer LA (2011) Eosinophils in innate immunity: an evolving story. Cell Tissue Res 343(1):57–83. https://doi.org/10.1007/s00441-010-1049-6
Kobayashi T, Kouzaki H, Kita H (2010) Human eosinophils recognize endogenous danger signal crystalline uric acid and produce proinflammatory cytokines mediated by autocrine ATP. J Immunol 184(11):6350–6358
Lee JJ, Jacobsen EA, Ochkur SI et al (2012) Human vs. mouse eosinophils: “That which we call an eosinophil, by any other name would stain as red”. J Allergy Clin Immunol 130(3):572–584. https://doi.org/10.1016/j.jaci.2012.07.025
Sokol CL, Medzhitov R (2010) Role of basophils in the initiation of Th2 responses. Curr Opin Immunol 22:73–77
Min B, Brown MA, LeGros G (2012) Understanding the roles of basophils: breaking dawn. Immunology 135(3):192–197. https://doi.org/10.1111/j.1365-2567.2011.03530.x
Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550. https://doi.org/10.1146/annurev.immunol.021908.132612
Schroder K, Zhou R, Tschopp J (2010) The NLRP3 inflammasome: a sensor for metabolic danger? Science 327(5963):296–300. https://doi.org/10.1126/science.1184003
Caligiuri MA (2008) Human natural killer cells. Blood 112(3):461–910
Orange JS (2013) Natural killer cell deficiency. J Allergy Clin Immunol 132(3):515–526. https://doi.org/10.1016/j.jaci.2013.07.020
Ham H, Billadeau DD (2014) Human immunodeficiency syndromes affecting human natural killer cell cytolytic activity. Front Immunol 5:2. https://doi.org/10.3389/fimmu.2014.00002
Rothenberg EV (2014) Transcriptional control of early T and B cell developmental choices. Annu Rev Immunol 32:283–321. https://doi.org/10.1146/annurev-immunol-032712-100024
LeBien TW, Tedder TF (2008) B lymphocytes: how they develop and function. Blood 112:1570–1580
Zhu J, Paul WE (2008) CD4 T cells: fates, functions, and faults. Blood 112(5):1557–1569. https://doi.org/10.1182/blood-2008-05-078154
Wan YY (2014) GATA3: a master of many trades in immune regulation. Trends Immunol 35(6):233–242. https://doi.org/10.1016/j.it.2014.04.002
Bonilla FA, Oettgen HC (2010) Adaptive immunity. J Allergy Clin Immunol 125(2):S33–S40
Artis D, Spits H (2015) The biology of innate lymphoid cells. Nature 517:293–301. https://doi.org/10.1038/nature14189
Hepworth MR, Sonnenberg GF (2014) Regulation of the adaptive immune system by innate lymphoid cells. Curr Opin Immunol 27:75–82. https://doi.org/10.1016/j.coi.2014.01.013
Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ (2009) Skin immune sentinels in health and disease. Nat Rev Immunol 9:679–691
Franchi L, Warner N, Viani K, Nuñez G (2009) Function of Nod-like receptors in microbial recognition and host defence. Immunol Rev 227(1):106–128
Halverson R, Torres R, Pelanda R (2004) Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nat Immunol 5(6):645–650. https://doi.org/10.1038/ni1076 (PMID 15156139)
Schwarz BA, Bhandoola A (2006) Trafficking from the bone marrow to the thymus: a prerequisite for thymopoiesis. Immunol Rev 209:47–57
Takaba H, Morishita Y, Tomofuji Y et al (2015) Fezf2 orchestrates a thymic program of self-antigen expression for immune tolerance. Cell 163:975–987
Sakaguchi S, Takahashi T, Nishizuka Y (1982) Study on cellular events in post-thymectomy autoimmune oophoritis in mice. I. Requirement of Lyt-1 effector cells for oocytes damage after adoptive transfer. J Exp Med 156:1565–1576
Warrington R, Watson W, Kim HL, Antonetti FR (2011) An introduction to immunology and immunopathology. Allergy Asthma Clin Immunol 7(Suppl 1):S1
International Agency for Research on Cancer (IARC) (1995) Monographs on the evaluation of carcinogenic risks to humans, no. 64.1, human papillomavirus (HPV) infection. https://www.ncbi.nlm.nih.gov/books/NBK424405/. Accessed 8 Oct 2018
Carter JJ, Koutsky LA, Hughes JP et al (2000) Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181(6):1911–1919
Af Geijersstam V, Kibur M, Wang Z et al (1998) Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 177:1710–1714
Lehtinen M, Pawlita M, Zumbach K et al (2003) Evaluation of antibody response to human papillomavirus early proteins in women in whom cervical cancer developed 1 to 20 years later. Am J Obstet Gynecol 188(1):49–55
Leon S, Sánchez R, Patarroyo MA et al (2009) Prevalence of HPV-DNA and anti-HPV antibodies in women from Girardot, Colombia. Sex Transm Dis 36(5):290–296. https://doi.org/10.1097/OLQ.0b013e318195762c
de Jong A, van Poelgeest MI, van der Hulst JM et al (2004) Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 64:5449–5455
Woo YL, van den Hende M, Sterling JC et al (2010) A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int J Cancer 126:133–141
Chan PKS, Liu SJ, Cheung TH et al (2010) T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer. Clin Vaccine Immunol 17(9):1315–1321. https://doi.org/10.1128/CVI.00105-10
Chan PKS, Liu SJ, Cheung JL et al (2011) T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer. J Med Virol 83(6):1023–1030. https://doi.org/10.1002/jmv.21889
van der Burg SH, Piersma SJ, de Jong A et al (2007) Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci USA 104(29):12087–12092
Molling JW, de Grujil TD, Glim J et al (2007) CD4(+) CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 121(8):1749–1755
Benton C, Shahidulhah H, Hunter JAA (1992) Human papillomaviruses in the immuno-suppressed; pp 23–26 in IARC Working Group on the evaluation of carcinogenic risk to humans. Human papillomaviruses. Lyon (FR): International Agency for Research on Cancer; 1995 (IARC monographs on the evaluation of carcinogenic risks to humans, no. 64.). https://www.ncbi.nlm.nih.gov/books/NBK424408/. Accessed 8 Oct 2018
Braun L (1994) Role of human immunodeficiency virus infection in the pathogenesis of human papillomavirus-associated cervical neoplasia. Am J Pathol 144:209–214
Wheeler CM, Hunt WC, Schiffman M, Castle PE (2006) Human papillomavirus genotypes and the cumulative 2-year risk of cervical pre-cancer. J Infect Dis 194:1291–1299
Stanley M (2010) HPV—immune response to infection and vaccination. Infect Agents Cancer 5:19
Giannini SL, Hanon E, Moris P et al (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24(33–34):5937–5949
De Carvalho N, Teixeira J, Roteli-Martins CM et al (2010) Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 28:6247–6255
Scherpenisse M, Schepp RM, Mollers M et al (2013) Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One 8(9):e74797. https://doi.org/10.1371/journal.pone.0074797
Handisurya A, Schellenbacher C, Haitel A et al (2016) Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids. Br J Cancer 114:409–416. https://doi.org/10.1038/bjc.2015.462
Ferris DG, Samakoses R, Block SL et al (2017) 4-Valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years. Pediatrics 140(6):e20163947
Narayan S, Choyce A, Linedale R et al (2009) Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4+ CD25+ T cells. Eur J Immunol 39:481–490
Varricchio F, Iskander J, Destefano F et al (2004) Understanding vaccine safety information from the vaccine adverse event reporting system. Pediatr Infect Dis J 23(4):287–294
Xie J, Zhao L, Zhou S, He Y (2016) Statistical and ontological analysis of adverse events associated with monovalent and combination vaccines against hepatitis A and B diseases. Sci Rep 6:34318. https://doi.org/10.1038/srep34318
Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine (2015) Beyond myalgic encephalomyelitis/chronic fatigue syndrome: redefining an illness. National Academies Press (US), Washington (DC). https://www.ncbi.nlm.nih.gov/books/NBK274235/. Accessed 8 Oct 2018
Dantoft TM, Ebstrup JF, Linneberg A et al (2017) Cohort description: the Danish study of functional disorders. Clin Epidemiol 9:127–139
Wong R, Lopaschuk G, Zhu G et al (1992) Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest 102(6):1716–1722
Filler K, Lyon D, Bennett J et al (2014) Association of mitochondrial dysfunction and fatigue: a review of the literature. BBA Clin 1:12–23
Rutherford G, Manning P, Newton JL (2016) Understanding muscle dysfunction in chronic fatigue syndrome. J Aging Res 2016:2497348. https://doi.org/10.1155/2016/2497348
Lacourt TE, Vichaya EG, Chiu GS et al (2018) The high costs of low-grade inflammation: persistent fatigue as a consequence of reduced cellular-energy availability and non-adaptive energy expenditure. Front Behav Neurosci 12:78. https://doi.org/10.3389/fnbeh.2018.00078
Blomberg J, Gottfries CG, Elfaitouri A et al (2018) Infection elicited autoimmunity and myalgic encephalomyelitis/chronic fatigue syndrome: an explanatory model. Front Immunol (Hypothesis Theory) 9:229. https://doi.org/10.3389/fimmu.2018.00229
Montoya JG, Holmes TH, Anderson JN et al (2017) Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proc Natl Acad Sci USA 114:E7150–E7158. https://doi.org/10.1073/pnas.1710519114
Brenu EW, van Driel ML, Staines DR et al (2011) Immunological abnormalities as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med 9:81
Hardcastle SL, Brenu EW, Johnston S et al (2015) Longitudinal analysis of immune abnormalities in varying severities of chronic fatigue syndrome/myalgic encephalomyelitis patients. J Transl Med 13:299. https://doi.org/10.1186/s12967-015-0653-3
Nacul L, O’Donovan DG, Eliana M et al (2014) Considerations in establishing a post-mortem brain and tissue bank for the study of myalgic encephalomyelitis/chronic fatigue syndrome: a proposed protocol. BMC Res Notes 7:370
Schondorf R, Benoit J, Wein T, Phaneuf D (1999) Orthostatic intolerance in the chronic fatigue syndrome. J Auton Nerv Syst 75(2–3):192–201
Kanduc D (2009) Quantifying the possible cross-reactivity risk of an HPV16 vaccine. J Exp Ther Oncol 8(1):65–76
Kanduc D, Shoenfeld Y (2016) From HBV to HPV: designing vaccines for extensive and intensive vaccination campaigns worldwide. Autoimmun Rev 15(11):1054–1061. https://doi.org/10.1016/j.autrev.2016.07.030
Lu C, Diehl SA, Noubade R et al (2010) Endothelial histamine H1 receptor signaling reduces blood-brain barrier permeability and susceptibility to autoimmune encephalomyelitis. Proc Natl Acad Sci USA 107(44):18967–18972
Shanas U, Bhasin R, Sutherland AK et al (1998) Brain mast cells lack the c-kit receptor: immunocytochemical evidence. J Neuroimmunol 90(2):207–211
Letourneau R, Rozniecki JJ, Dimitriadou V, Theoharides TC (2003) Ultrastructural evidence of brain mast cell activation without degranulation in monkey experimental allergic encephalomyelitis. J Neuroimmunol 145:18–26
Twisk FNM (2014) The status of and future research into myalgic encephalomyelitis and chronic fatigue syndrome: the need of accurate diagnosis, objective assessment, and acknowledging biological and clinical subgroups. Front Physiol 5:109. https://doi.org/10.3389/fphys.2014.00109
Balagopalan L, Sherman E, Barr VA, Samelson LE (2011) Imaging techniques for assaying lymphocyte activation in action. Nat Rev Immunol 11(1):21–33
Schietinger A, Delrow JJ, Basom RS et al (2012) Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335:723–727
Schietinger A, Greenberg PD (2014) Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol 35(2):51–60. https://doi.org/10.1016/j.it.2013.10.001
Aderem A (2005) Systems biology: its practice and challenges. Cell 20:511–513
Pulendran B, Ahmed R (2006) Translating innate immunity into immunological memory: implications for vaccine development. Cell 124:849–863
Daniel E, Zak DE, Aderem A (2009) Systems biology of innate immunity. Immunol Rev 227(1):264–282. https://doi.org/10.1111/j.1600-065X.2008.00721.x
Querec TD, Akondy RS, Lee EK et al (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10:116–125
Pulendran B, Li S, Nakaya HI (2010) Systems vaccinology. Immunity 33(4):516–529. https://doi.org/10.1016/j.immuni.2010.10.006
Nakaya HI, Li S, Pulendran B (2012) Systems vaccinology: learning to compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev Syst Biol Med 4:193–205
Jangi S, Gandhi R, Cox LM, Li N et al (2016) Alterations of the human gut microbiome in multiple sclerosis. Nat Commun 7:12015. https://doi.org/10.1038/ncomms12015
Nyamundanda G, Gormley IC, Fan Y et al (2013) MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach. BMC Bioinform 14:338
Muller P, Parmigiani G, Robert C, Rousseau J (2004) Optimal sample size for multiple testing. J Am Stat Assoc 99(468):990–1000
Tibshirani R (2006) A simple method for assessing sample sizes in microarray experiments. BMC Bioinform 7:106
Lin WJ, Hsueh HM, Chen JJ (2010) Power and sample size estimation in microarray studies. BMC Bioinform 11:48
Gonzalez E, van Liempd S, Conde-Vancells J, Gutierrez-de Juan V, Perez-Cormenzana M, Mayo R, Berisa A, Alonso C, Marquez CA, Barr J, Lu SC, Mato JM, Falcon-Perez JM (2012) Serum UPLC-MS/MS metabolic profiling in an experimental model for acute-liver injury reveals potential biomarkers for hepatotoxicity. Metabolomics 8(6):997–1011. https://doi.org/10.1007/s11306-011-0329-9
Timmons JA, Knudsen S, Rankinen T et al (2010) Using molecular classification to predict gains in maximal aerobic capacity following endurance exercise training in humans. J Appl Physiol 108:1487–1496
Gallagher IJ, Scheele C, Keller P et al (2010) Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med 2:9
Scherpenisse M, Schepp RM, Mollers M et al (2013) Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination. Clin Vaccine Immunol 20(8):1329–1332. https://doi.org/10.1128/CVI.00153-13
Pritchard CC, Cheng HH, Tewari M (2015) MicroRNA profiling: approaches and considerations. Nat Rev Genet 13(5):358–369. https://doi.org/10.1038/nrg3198
Bizuayehu TT, Lanes CF, Furmanek T et al (2012) Differential expression patterns of conserved miRNAs and isomiRs during Atlantic halibut development. BMC Genom 13:11. https://doi.org/10.1186/1471-2164-13-11
Baker M (2011) Metabolomics:from small molecules to big ideas. Nat Methods 8(2):117–121
Duportet X, Aggio RB, Carneiro S, Villas-Bôas S (2012) The biological interpretation of metabolomics data can be misled by the extraction method used. Metabolomics 8(3):410–421
Martinaz-Arranz I, Mayo R, Perez-Cormenzana M et al (2015) Data in support of enhancing metabolomics research through data mining. Data Br 3:155–164
Guo L, Milburn MV, Ryals JA et al (2015) Plasma metabolomics profiles enhance precision medicine for volunteers of normal health. Proc Natl Acad Sci. https://doi.org/10.1073/pnas.1508425112
Nagana Gowda GA, Zhang S, Gu H et al (2008) Metabolomics-based methods for early disease diagnostics: a review. Exp Rev Mol Diagn 8(5):617–633. https://doi.org/10.1586/14737159.8.5.617
Wishart DS, Tzur D, Knox C et al (2007) HMDB: the human metabolome database. Nucleic Acids Res 35:D521–D526. https://doi.org/10.1093/nar/gkl923
Wen L, Ley RE, Volchkov PV et al (2008) Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 455(7216):1109–1113
Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 5:427–434. https://doi.org/10.1038/nature06005
Arthur JC, Perez-Chanona E, Mühlbauer M et al (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 5:120–123
Delzenne NM, Neyrinck AM, Backhed F, Cani PD (2011) Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 5:639–646
Foster JA, McVey Neufeld KA (2013) Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci 36(5):305–312
Belkaid Y, Hand T (2014) Role of the microbiota in immunity and inflammation. Cell 157(1):121–141
Turovskiy Y, Sutyak NK, Chikindas ML (2011) The aetiology of bacterial vaginosis. J Appl Microbiol 110:1105–1128
Iwase T, Uehara Y, Shinji H et al (2010) Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature 465:346–349
Kamada N, Chen GY, Inohara N, Nunez G (2013) Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 14:685–690
Pacheco AR, Curtis MM, Ritchie JM et al (2012) Fucose sensing regulates bacterial intestinal colonization. Nature 492:113–117
Gantois I, Ducatelle R, Pasmans F et al (2006) Butyrate specifically down-regulates salmonella pathogenicity island 1 gene expression. Appl Environ Microbiol 72:946–949 [PubMed: 16391141]
Molloy MJ, Grainger JR, Bouladoux N et al (2013) Intraluminal containment of commensal outgrowth in the gut during infection-induced dysbiosis. Cell Host Microbe 14:318–328
Sansonetti PJ, Di Santo JP (2007) Debugging how bacteria manipulate the immune response. Immunity 26:149–161
Manzel A, Muller DN, Hafler DA et al (2014) Role of “Western Diet” in inflammatory autoimmune diseases. Curr Allergy Asthma Rep 14(1):404. https://doi.org/10.1007/s11882-013-0404-6
Wu HJ, Ivanov II, Darce J et al (2010) Gut residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32:815–827 (PubMed: 20620945)
Richter M, Rosselló-Móra R (2009) Shifting the genomic gold standard for the prokaryotic species definition. Proc Natl Acad Sci 106:19126–19131
Kearse M, Moir R, Wilson A et al (2012) Geneious basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 28:1647–1649
Khatri P, Sirota M, Butte AJ (2012) Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput Biol 8:e1002375
Vrahatis AG, Dimitrakopoulou K, Balomenos P et al (2015) CHRONOS: a time-varying method for microRNA-mediated sub-pathway enrichment analysis. Bioinformatics 32:884–892
Vrahatis AG, Balomenos P, Tsakalidis AK, Bezerianos A (2016) DEsubs: an R package for flexible identification of differentially expressed subpathways using RNA-seq experiments. Bioinformatics 32:3844–3846
Kanehisa FM, Tanabe M, Sato Y, Morishima K (2017) KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45:D353–D361
Judeh T, Johnson C, Kumar A, Zhu D (2013) TEAK: topology enrichment analysis framework for detecting activated biological subpathways. Nucleic Acids Res 41:1425–1437
Li C, Han J, Yao Q et al (2013) Subpathway-GM: identification of metabolic subpathways via joint power of interesting genes and metabolites and their topologies within pathways. Nucleic Acids Res 41:e101
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Campbell-Tofte, J., Vrahatis, A., Josefsen, K. et al. Investigating the aetiology of adverse events following HPV vaccination with systems vaccinology. Cell. Mol. Life Sci. 76, 67–87 (2019). https://doi.org/10.1007/s00018-018-2925-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-018-2925-6